CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value

Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001; 357: 127-35.

Duan HJ, Li XY, Liu C, Deng XL. Chemokine-like factor-like marvel transmembrane domain-containing family in autoimmune diseases. Chin Med J (Engl). 2020; 133: 951-8.

Zhang JW, Liu TF, Chen XH, Liang WY, Feng XR, Wang L, et al. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function. Gene. 2017; 624: 56-65.

Liu Q, Su Y, Jiang GC, Zhou ZL, Liu BC, Bu L, et al. Change of CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non-small cell lung cancer. Chin Med J (Engl). 2013; 126: 3006-12.

Hu H, Chen JW, Xu KX, Wang D, Wang Y, Wang GW, et al. Expressions of CMTM8 and e-cadherin in primary and metastatic clear cell renal cell carcinoma. Beijing Da Xue Xue Bao Yi Xue Ban. 2013; 45: 537-41.

Li P, Liu K, Li L, Yang M, Gao W, Feng J, et al. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. Int J Gynecol Cancer. 2011; 21: 1248-55.

Niu J, Li H, Zhang Y, Li J, Xie M, Li L, et al. Aberrant expression of CKLF-like marvel transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia. Leuk Res. 2011; 35: 771-6.

Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CPG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009; 69: 5194-201.

Shao L, Cui Y, Li H, Liu Y, Zhao H, Wang Y, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 2007; 13: 5756-62.

Zhang W, Qi H, Mo X, Sun Q, Li T, Song Q, et al. CMTM8 is frequently downregulated in multiple solid tumors. Appl Immunohistochem Mol Morphol. 2017; 25: 122-8.

Xie J, Yuan Y, Liu Z, Xiao Y, Zhang X, Qin C, et al. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities. Clin Transl Oncol. 2014; 16: 402-9.

Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017; 549: 106-10.

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017; 549: 101-5.

Gao D, Hu H, Wang Y, Yu W, Zhou J, Wang X, et al. CMTM8 inhibits the carcinogenesis and progression of bladder cancer. Oncol Rep. 2015; 34: 2853-63.

Si J, Zhang P, Tian D, Wang X, Ma Y, Zhang J, et al. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. World J Surg Oncol. 2017; 15: 34.

Su Y, Lin Y, Zhang L, Liu B, Yuan W, Mo X, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2014; 105: 26-34.

Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 2018; 35: 233-43.

Zhang S, Pei X, Hu H, Zhang W, Mo X, Song Q, et al. Functional characterization of the tumor suppressor CMTM8 and its association with prognosis in bladder cancer. Tumour Biol. 2016; 37: 6217-25.

Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics. 2003; 81: 609-17.

Zhong J, Wang Y, Qiu X, Mo X, Liu Y, Li T, et al. Characterization and expression profile of CMTM3/ CKLFSF3. J Biochem Mol Biol. 2006; 39: 537-45.

Shao L, Guo X, Plate M, Li T, Wang Y, Ma D, et al. CMTM5-v1 induces apoptosis in cervical carcinoma cells. Biochem Biophys Res Commun. 2009; 379: 866-71.

Li H, Guo X, Shao L, Plate M, Mo X, Wang Y, et al. CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway. BMB Rep. 2010; 43: 182-7.

Li T, Cheng Y, Wang P, Wang W, Hu F, Mo X, et al. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2015; 34: 122.

Plate M, Li T, Wang Y, Mo X, Zhang Y, Ma D, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on hela cell growth through inducing G2/M phase accumulation. Mol Cells. 2010; 29: 355-61.

Li D, Jin C, Yin C, Zhang Y, Pang B, Tian L, et al. An alternative splice form of CMTM8 induces apoptosis. Int J Biochem Cell Biol. 2007; 39: 2107-19.

Song HS, Shi S, Lu XZ, Gao F, Yan L, Wang Y, et al. Intracellular CMTM2 negatively regulates human immunodeficiency virus type-1 transcription through targeting the transcription factors AP-1 and CREB. Chin Med J (Engl). 2010; 123: 2440-5.

Wang L, Wu C, Zheng Y, Qiu X, Wang L, Fan H, et al. Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. Int J Biochem Cell Biol. 2004; 36: 1492-501.

Li H, Li J, Su Y, Fan Y, Guo X, Li L, et al. A novel 3p22.3 gene CMTM7 represses oncogenic egfr signaling and inhibits cancer cell growth. Oncogene. 2014; 33: 3109-18.

Shen Z, Chen X, Li Q, Zhou C, Xu Y, Yu R, et al. Elevated methylation of CMTM3 promoter in the male laryngeal squamous cell carcinoma patients. Clin Biochem. 2016; 49: 1278-82.

Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F. CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. Ann Transl Med. 2018; 6: 54.

Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, et al. DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene. 2017; 630: 1-7.

Zhang H, Nan X, Li X, Chen Y, Zhang J, Sun L, et al. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma. Biochem Biophys Res Commun. 2014; 447: 304-10.

Jin Y, Qin X, Jia G. SOX10-dependent CMTM7 expression inhibits cell proliferation and tumor growth in gastric carcinoma. Biochem Biophys Res Commun. 2018; 507: 91-9.

Lu M, Huang Y, Sun W, Li P, Li L, Li L. Mir-135b-5p promotes gastric cancer progression by targeting CMTM3. Int J Oncol. 2018; 52: 589-98.

Guan L, Ji D, Liang N, Li S, Sun B. Up-regulation of mir-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5. J Cell Mol Med. 2018; 22: 3434-41.

Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E. Microrna-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer. 2009; 125: 1407-13.

Li G, Wu Z, Peng Y, Liu X, Lu J, Wang L, et al. Microrna-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells. Cancer Lett. 2010; 299: 29-36.

Nakata K, Ohuchida K, Mizumoto K, Kayashima T, Ikenaga N, Sakai H, et al. Microrna-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011; 150: 916-22.

Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang JR, et al. Mir-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer. 2016; 16: 806.

Wang Y, Li T, Qiu X, Mo X, Zhang Y, Song Q, et al. CMTM3 can affect the transcription activity of androgen receptor and inhibit the expression level of PSA in LNCaP cells. Biochem Biophys Res Commun. 2008; 371: 54-8.

Delic S, Thuy A, Schulze M, Proescholdt MA, Dietrich P, Bosserhoff AK, et al. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets. Genes Chromosomes Cancer. 2015; 54: 433-43.

Wang J, Zhang G, Zhang Y, Luo Y, Song Q, Qiu X, et al. CMTM1_v17 is a novel potential therapeutic target in breast cancer. Oncol Rep. 2014; 32: 1829-36.

Jin C, Wang Y, Han W, Zhang Y, He Q, Li D, et al. CMTM8 induces caspase-dependent and -independent apoptosis through a mitochondria-mediated pathway. J Cell Physiol. 2007; 211: 112-20.

Li Z, Xie J, Wu J, Li W, Nie L, Sun X, et al. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS One. 2014; 9: e88965.

Yuan W, Liu B, Wang X, Li T, Xue H, Mo X, et al. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer. Cancer Lett. 2017; 386: 77-86.

Guo X, Zhang S, Tan S, Bei C, Zhang H, Zhu X, et al. Downregulated CMTM2 poses potential clinical significance in hepatocellular carcinoma. DNA Cell Biol. 2020; 39: 683-9.

Li W, Zhang S. CKLF-like marvel transmembrane domain-containing member 3 (CMTM3) inhibits the proliferation and tumorigenisis in hepatocellular carcinoma cells. Oncol Res. 2017; 25: 285-93.

Xu G, Dang C. CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell Int. 2017; 17: 113.

Zhang W, Mendoza MC, Pei X, Ilter D, Mahoney SJ, Zhang Y, et al. Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem. 2012; 287: 11850-8.

Liu B, Su Y, Li T, Yuan W, Mo X, Li H, et al. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation. Oncotarget. 2015; 6: 41092-107.

Cao L, Yang C, Zhu B, Zhang G, Zhao N, Liu X, et al. A novel protein CMTM1-v5 specifically induced human lymphoma cells apoptosis in vitro and in vivo. Exp Cell Res. 2019; 385: 111623.

Zhang H, Zhang J, Nan X, Li X, Qu J, Hong Y, et al. CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma. Tumour Biol. 2015; 36: 7849-58.

Guo X, Li T, Wang Y, Shao L, Zhang Y, Ma D, et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. Biochem Biophys Res Commun. 2009; 387: 139-42.

Hu F, Yuan W, Wang X, Sheng Z, Yuan Y, Qin C, et al. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells. Clin Transl Oncol. 2015; 17: 632-9.

Xiao Y, Yuan Y, Zhang Y, Li J, Liu Z, Zhang X, et al. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo. Clin Transl Oncol. 2015; 17: 431-7.

Yuan Y, Sheng Z, Liu Z, Zhang X, Xiao Y, Xie J, et al. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells. J Cancer. 2020; 11: 3762-70.

Cai B, Xiao Y, Li Y, Zheng S. CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis. Oncol Lett. 2017; 14: 1536-42.

Schafer KA. The cell cycle: a review. Vet Pathol. 1998; 35: 461-78.

Wenzel ES, Singh ATK. Cell-cycle checkpoints and aneuploidy on the path to cancer. In Vivo. 2018; 32: 1-5.

Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018; 28: 911-25.

Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012; 12: 553-63.

Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018; 12: 3-20.

Chen SQ, Du Y, Huang YM, Wang X, Gu QL, Dong ZM. Effects of novel human chemokine-like factor superfamily 8 on proliferation and EGFR expression of HL-60 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007; 15: 458-61.

Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016; 166: 21-45.

Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016; 35: 645-54.

Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017; 19: 518-29.

Yuan W, Li T, Mo X, Wang X, Liu B, Wang W, et al. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway. Oncotarget. 2016; 7: 29507-19.

Jin C, Ding P, Wang Y, Ma D. Regulation of EGF receptor signaling by the marvel domain-containing protein CKLFSF8. FEBS Lett. 2005; 579: 6375-82.

Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016; 8: 603-19.

Delavallee L, Cabon L, Galan-Malo P, Lorenzo HK, Susin SA. AIF-mediated caspase-independent necroptosis: a new chance for targeted therapeutics. IUBMB Life. 2011; 63: 221-32.

Dyshlovoy SA, Rast S, Hauschild J, Otte K, Alsdorf WH, Madanchi R, et al. Frondoside a induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. Leuk Lymphoma. 2017; 58: 2905-15.

Topalian SL, Wolchok JD, Chan TA, Mellman I, Palucka K, Banchereau J, et al. Immunotherapy: the path to win the war on cancer? Cell. 2015; 161: 185-6.

Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015; 125: 3335-7.

Miyazaki A, Yogosawa S, Murakami A, Kitamura D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS One. 2012; 7: e31829.

Zhang Y, Wang JY, Han W. A role for CMTM7 in BCR expression and survival in B-1a but not B-2 cells. Int Immunol. 2014; 26: 47-57.

Bei C, Zhang Y, Wei R, Zhu X, Wang Z, Zeng W, et al. Clinical significance of CMTM4 expression in hepatocellular carcinoma. Onco Targets Ther. 2017; 10: 5439-43.

Koh YW, Han JH, Haam S, Jung J, Lee HW. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncoimmunology. 2019; 8: e1629261.

Zugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS, et al. Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small cell lung cancer. J Thorac Oncol. 2019; 14: 2084-96.

Imamovic D, Vranic S. Novel regulators of pd-l1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. Ann Transl Med. 2017; 5: 467.

Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, et al. PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell. 2019; 74: 1215-26.e4.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.

Yuan YQ, Zhang YX, Liu ZH, Qin CP, Sheng ZZ, Xu T, et al. Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer. Beijing Da Xue Xue Bao Yi Xue Ban. 2015; 47: 571-6.

Xu T, Li J, Xiao YB, Liu ZH, Li Q, Wang XF. CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2. Beijing Da Xue Xue Bao Yi Xue Ban. 2010; 42: 386-90.